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About 5-10 % of chronic myelogenous leukemia (CML) patients show variant Philadelphia (Ph) translocations. The
formation mechanisms and clinical significance of variant Ph translocations remain unclear. We report a CML case
with a novel five-way complex translocation. Although the result of initial G-banding was 46,XY,t(7;11;9)(q22;q13;
q34),t(9;22)(q34;q11.2), fluorescence in situ hybridization (FISH) demonstrated t(7;11;9;22;9)(q22;q13;q34;q11.2;q34)
consisting of sequential rearrangements involving five chromosomes. The patient was successfully treated by
imatinib and obtained a major molecular response. To our knowledge, this is the tenth CML case with a
complicated Ph translocation involving five chromosomes and the third one treated by imatinib. Good response
with imatinib therapy suggested that a single-event rearrangement was involved in the chromosomal changes.
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Chronic myelogenous leukemia (CML) is a clonal myelo-
proliferative disorder of primitive hematopoietic stem
cells. Most CML patients show a Philadelphia (Ph)
chromosome with the characteristic t(9;22)(q34;q11.2)
translocation. However, about 5-10 % of Ph positive
patients with CML show variant translocations. The for-
mation mechanisms and clinical significance of variant
Ph translocations remain unclear.
We describe a CML case with a novel five-way chromo-
somal translocation t(7;11;9;22;9)(q22;q13;q34;q11.2;q34),
who has been successfully treated by imatinib. To our
knowledge, this is the tenth CML case with a complicated
Ph translocation involving five chromosomes, and the
third one treated by imatinib.Case presentation
The patient was 58-year-old Japanese male with no signifi-
cant medical history. He was found to have increased
white blood cell count (WBC) at a medical checkup at his
workplace and referred to our hospital. The laboratory* Correspondence: ynakam@saitama-med.ac.jp
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reproduction in any medium, provided the ordata on admission showed that his WBC was 19.1× 109/L,
with a differential of 67.5 % neutrophils, 5.5 % myelocytes,
3.0 % metamyelocytes, 6.0 % basophils, 1.5 % eosinophils,
3.0 % monocytes, 13.5 % lymphocytes. Hemoglobin con-
centration of 13.0 g/dL was within a normal range and
platelet count of 390 ×109/L was slightly elevated. Neutro-
phil alkaline phosphatase (NAP) score was decreased to 79
(control score, 170–285). Bone marrow aspirate showed
marked hypercellularity. Reverse-transcription polymerase
chain reaction (RT-PCR) of RNA from his bone marrow
cells amplified major BCR/ABL chimeric transcript (b3a2
type). He was diagnosed as having CML in the chronic
phase, then received treatment with orally imatinib at daily
of 400 mg. He obtained a complete cytogenetic response
as well as a major molecular response (MMR), as BCR/
ABL transcripts have not been detected by quantitative
RT-PCR analysis after thirteen months treatment. The
MMR status has been maintained for 44 months.
G-banding chromosomal analysis of the bone marrow
cells presented 46,XY,t(7;11;9)(q22;q13;q34),t(9;22)(q34;
q11.2) [20/20] (Figure 1A). After imatinib treatment,
karyotype of the patient’s bone marrow cells showed 46,
XY [20/20].
To confirm these cytogenetic aberrations, we performed
Spectral karyotyping (SKY) analysis with a SkyPaint kitLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Figure 1 (A) G-banded karyotype of the bone marrow cells. The karyotype was initially decided as 46,XY,t(7;11;9)(q22;q13;q34),t(9;22)(q34;
q11.2). Arrows indicate rearranged chromosomes. (B) Spectral karyotyping of the metaphase of the patient’s leukemic cells spread after spectrum-
based classification. Chromosomes were assigned a pseudocolor according to the measured spectrum. Four derivative chromosomes, der(9)t(9;11)
(q34;q13), der(9)t(9;22)(q34;q11), der(11)t(7;11)(q22;q13) and der(22)t(9;22)(q34;q11) and the truncated chromosome 7 were indicated by arrows.
The grayscale images are reverse DAPI; the colored images, SKY. (C) Normal SKY image.
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shown in Figure 1B, SKY confirmed four derivative chro-
mosomes, der(9)t(9;11)(q34;q13), der(9)t(9;22)(q34;q11),
der(11)t(7;11)(q22;q13), and der(22)t(9;22)(q34;q11). SKY
could not visualize the small segment 9q34-9qter on the
der(7)t(7;9)(q22;q34). The size of this segment was sup-
posed to be smaller than a minimum genomic alteration
that SKY could detect.
For further characterization of these translocations, we
next performed fluorescence in situ hybridization (FISH)
analyses. In order to detect the BCR/ABL rearrangement
and determine the 9q34 breakpoints, the LSI BCR/ABL
ES Dual Color Translocation Probe Set (Vysis, Inc.) was
used (assay 1). This probe set is a mixture of an ABL
probe, which covers not only the ABL but also the
centromeric located ASS gene (Spectrum Orange) and aBCR probe (Spectrum Green). In assay 1, one yellow
(red-green) signal, showing the BCR/ABL fusion, one BCR
(green), one ASS-ABL (larger red), and one ASS (smaller
red) signal were detected (Figure 2A). This finding indi-
cated that the two der(9) chromosomes had different 9q34
breakpoints, one within the ABL, generating the BCR/ABL
fusion gene, the other within or centromeric to the ASS.
Additionally, we used two types of probe. One is the
CEP7 (Vysis, Inc.) (Spectrum Green) that hybridizes to
the centromere of chromosome 7 (assay 2). The other is
the mixture consisted of 11p (Spectrum Green), 11q
(Spectrum Orange), 18p (Spectrum Green and Spectrum
Orange) and 18 centromeric (Spectrum Aqua) probes
(Vysis, Inc. ) (assay 3). Assay 2 indicate that the ASS-
ABL segment (larger red signal) from the chromosome 9
was on der(7) with CEP7 signal. The fusion BCR/ABL
Figure 2 FISH analyses with (A) ABL and BCR probes, (B) additional CEP7 probe and (C) additional 11p, 11q and chromosome 18
probes. FISH probes and chromosomes of attention were indicated by arrows and dashed lines, respectively. (A) One yellow (red-green) signal,
showing the BCR/ABL fusion, one BCR (green), one ASS-ABL (larger red), and one ASS (smaller red) signal were detected. (B) The segment (ASS-ABL,
larger red signal) from the chromosome 9 was on der(7). The fusion BCR/ABL signal was on der (22), and the smaller red signal (ASS) was retained
on the other chromosome 9. (C) The larger red signal, 11q, was on der(9) which retained the smaller red signal ASS.
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was retained on the other chromosome 9 (Figure 2B). In
assay 3, the larger red signal, 11q, was on one of der(9)
which retained the smaller red signal ASS (Figure 2C),
indicating that the 11q segment was translocated to a
chromosome 9 with rearrangement within the ABL, but
not to the other from which ASS-ABL was translocated
to der(7).
The results from G-banding, SKY and FISH analyses
finally revised the karyotype as 46,XY,t(7;11;9;22;9)(q22;
q13;q34;q11.2;q34) (Figure 3). We found nine other
CML cases with five-way translocation, two of which
were treated by imatinib [1-9] (Table 1). However, to our
knowledge, this combination has not reported so far
[10].
Two possible mechanisms have been postulated for
formation of variant translocations. One is a single-eventrearrangement via simultaneous breakage of several
chromosomes followed by mismatched joining [11]. The
other is a multi-step mechanism in which a classical Ph
translocation is followed by further translocation events
involving chromosomes 9 and 22 and other chromo-
somes [12]. These mechanisms may have prognostic im-
portance in that a single genomic rearrangement may
confer a similar prognosis to the classical Ph transloca-
tion, whereas a multi-step mechanism represents clonal
evolutions associated with a worse prognosis [13].
Conflicting data were reported on clinical relevance of
variant Ph translocation to tyrosine kinase inhibitor treat-
ment [14-16] and its clinical significance has not been
determined yet. Our case had achieved a MMR by imati-
nib therapy, suggesting that a single-event rearrangement
was involved in the chromosomal change. However, care-













Figure 3 Schema of the five-way translocation observed in this case. Chromosomes were painted to the same colors as in SKY and FISH
probes were shown by the side of chromosomes.
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instability.
Conclusions
We report a patient with CML presenting a complex
five-way translocation, t(7;11;9;22;9)(q22;q13;q34;q11.2;
q34). In our case, the initial finding on G-banding ana-
lysis suggested that an additional chromosomal aberra-
tion would occur independently from the Ph
translocation. Chromosomal breaks occurred on both
alleles of band 9q34 in the translocation, but only one ofTable 1 Previously reported CML cases with five-way transloc
Case no. Age/Sex Karyotype of five-way translocation
1 10/Male t(4;18;13;9;22)(q12;q11.2;q14;q34;q11.2)
2 23/Male t(9;22;15;19;10)
3 68/Not reported t(3;4;9;11;22)










BSF:Busulphan, VCR:Vincristine, PSL: Prednisolone, ADM:Adriamycin, CPA:Cyclophospthem was involved for the formation of BCR/ABL fusion.
FISH method identified sequential rearrangements in-
volving five chromosomes. Good response with imatinib
therapy suggested that a single-event rearrangement was
involved in the chromosomal changes.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this Journal.ations and the present case
Reference no. Treatment Outcome
[1] BSF Died 81months
[2] Not reported Not reported
[3] Not reported Died in benign phase
[4] BSF/VCR and PSL/ADM,
CPA and MTX
Died 33 months
[5] DNR,VCR,AND and PSL Died 34 months
[6] Chemotherapy Not reported
[7] Not reported Not reported
[8] GLI 41 months




hamide, MTX:Methotrexate, DNR:Daunorubicin, GLI:Imatinib, HU:Hydroxyurea.
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